Valneva SE (VALN) Cash from Financing Activities (2021 - 2026)

Valneva SE (VALN) posted quarterly Cash from Financing Activities of -$5.3 million for Q1 2026, up 16.0% year-on-year from -$4.6 million in Q1 2025, and up 49.93% on a QoQ basis from -$10.7 million in Q4 2025.

Valneva SE (VALN) Cash from Financing Activities (2021 - 2026) Analysis & Trends

Valneva SE (VALN) has reported Cash from Financing Activities for 6 consecutive years, with -$5.3 million the latest figure, recorded in Q1 2026.

  • Quarterly Cash from Financing Activities rose 16.0% year-over-year to -$5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $309523.6 (down 99.16% YoY) and the FY2025 annual result came in at -$706669.6, down 102.02% from the prior year.
  • Cash from Financing Activities grew to -$5.3 million in Q1 2026 per VALN's latest filing, from -$10.7 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for VALN reached as high as $10.8 billion in Q3 2023 and fell as low as -$10.8 billion in Q2 2023.
  • A 5-year average of $20.3 million and a median of -$632702.6 in 2025 frame the typical range for Cash from Financing Activities.
  • The largest YoY upside for Cash from Financing Activities was 57059.15% in 2023 against a maximum downside of 9205.77% in 2023.
  • Year by year, Cash from Financing Activities stood at $106.4 million in 2022, then tumbled by 60.48% to $42.0 million in 2023, then slumped by 112.42% to -$5.2 million in 2024, then sank by 104.01% to -$10.7 million in 2025, then jumped by 49.93% to -$5.3 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered -$5.3 million, -$10.7 million, and -$632702.6 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 30.14 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 68.63 Mn
4 NuCana 279.75 Bn 279.75 Bn - 9,311.16
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 238.74 Mn
10 Valneva SE 803.90 Mn 680.66 Mn 5.38 Mn -5.34 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -5.34 Mn
Mar 31, 2026 -5.34 Mn
Dec 31, 2025 -10.66 Mn
Dec 31, 2025 -10.66 Mn
Sep 30, 2025 -632,702.57
Sep 30, 2025 -632,702.57
Jun 30, 2025 16.93 Mn
Jun 30, 2025 16.93 Mn
Mar 31, 2025 -6.35 Mn
Mar 31, 2025 -6.35 Mn
Dec 31, 2024 -5.22 Mn
Dec 31, 2024 -5.22 Mn
Sep 30, 2024 59.02 Mn
Sep 30, 2024 59.02 Mn
Jun 30, 2024 -10.39 Mn
Jun 30, 2024 -10.39 Mn
Mar 31, 2024 -8.49 Mn
Mar 31, 2024 -8.49 Mn
Dec 31, 2023 42.04 Mn
Dec 31, 2023 42.04 Mn